Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALC CalciMedica	$2.91 +11.5%	$2.36	$1.42 ▼ $5.97	$40.66M	1.33	104,670 shs	28,763 shs
JSPR Jasper Therapeutics	$3.11 +2.6%	$4.16	$2.27 ▼ $26.05	$46.72M	2.7	312,765 shs	323,724 shs
PLUR Pluri	$4.97 +2.7%	$4.98	$3.33 ▼ $7.13	$39.15M	0.76	8,471 shs	9,885 shs
SNSE Sensei Biotherapeutics	$8.68 +15.7%	$7.87	$5.00 ▼ $17.40	$10.95M	0.26	31,493 shs	49,571 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALC CalciMedica	0.00%	+6.20%	+15.48%	+45.50%	-35.76%
JSPR Jasper Therapeutics	0.00%	+26.94%	-7.72%	-36.92%	-82.70%
PLUR Pluri	0.00%	+4.61%	-8.13%	-4.61%	-10.29%
SNSE Sensei Biotherapeutics	0.00%	+15.72%	+8.23%	+26.16%	-30.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CALC CalciMedica	3.3549 of 5 stars	3.5	5.0	0.0	2.3	3.3	0.0
JSPR Jasper Therapeutics	2.963 of 5 stars	4.3	4.0	0.0	1.0	1.7	0.0
PLUR Pluri	2.2476 of 5 stars	3.5	3.0	0.0	1.9	1.7	0.0
SNSE Sensei Biotherapeutics	4.5425 of 5 stars	3.7	3.0	4.8	2.5	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALC CalciMedica	3.00	Buy	$16.00	449.83% Upside
JSPR Jasper Therapeutics	2.60	Moderate Buy	$28.75	824.44% Upside
PLUR Pluri	3.00	Buy	$12.00	141.45% Upside
SNSE Sensei Biotherapeutics	3.33	Buy	$55.00	533.64% Upside

Current Analyst Ratings Breakdown

Latest SNSE, CALC, PLUR, and JSPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	JSPR Jasper Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$29.00 ➝ $25.00
8/5/2025	SNSE Sensei Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/8/2025	JSPR Jasper Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$5.00
7/8/2025	JSPR Jasper Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$70.00 ➝ $12.00
7/8/2025	JSPR Jasper Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$50.00 ➝ $20.00
7/8/2025	JSPR Jasper Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/7/2025	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
7/7/2025	JSPR Jasper Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
6/2/2025	PLUR Pluri	Industrial Alliance Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALC CalciMedica	N/A	N/A	N/A	N/A	$0.44 per share	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$1.56 per share	N/A
PLUR Pluri	$1.03M	37.83	N/A	N/A	$1.00 per share	4.97
SNSE Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$21.66 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALC CalciMedica	-$13.70M	-$1.60	N/A	N/A	N/A	N/A	-206.51%	-103.81%	N/A
JSPR Jasper Therapeutics	-$71.27M	-$5.24	N/A	N/A	N/A	N/A	-172.28%	-128.34%	N/A
PLUR Pluri	-$20.89M	-$5.53	N/A	∞	N/A	-2,563.29%	-4,191.91%	-85.40%	9/17/2025 (Estimated)
SNSE Sensei Biotherapeutics	-$30.16M	-$21.31	N/A	N/A	N/A	N/A	-72.13%	-61.35%	N/A

Latest SNSE, CALC, PLUR, and JSPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	JSPR Jasper Therapeutics	-$1.20	-$1.74	-$0.54	-$1.74	N/A	N/A
8/12/2025	Q2 2025	CALC CalciMedica	-$0.40	-$0.40	N/A	-$0.40	N/A	N/A
8/5/2025	Q2 2025	SNSE Sensei Biotherapeutics	-$6.20	-$3.91	+$2.29	-$3.91	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
PLUR Pluri	N/A	N/A	N/A	N/A	N/A
SNSE Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALC CalciMedica	1.39	5.45	5.66
JSPR Jasper Therapeutics	N/A	2.10	4.31
PLUR Pluri	51.65	4.81	4.81
SNSE Sensei Biotherapeutics	N/A	7.64	7.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALC CalciMedica	N/A
JSPR Jasper Therapeutics	79.85%
PLUR Pluri	16.59%
SNSE Sensei Biotherapeutics	10.50%

Insider Ownership

Company	Insider Ownership
CALC CalciMedica	41.55%
JSPR Jasper Therapeutics	4.60%
PLUR Pluri	25.93%
SNSE Sensei Biotherapeutics	23.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALC CalciMedica	30	13.97 million	8.17 million	No Data
JSPR Jasper Therapeutics	20	15.02 million	14.33 million	Optionable
PLUR Pluri	150	7.87 million	5.83 million	Optionable
SNSE Sensei Biotherapeutics	40	1.26 million	968,000	Not Optionable

SNSE, CALC, PLUR, and JSPR Headlines

Recent News About These Companies

Sensei Biotherapeutics Inc trading resumes

August 15 at 9:00 PM | msn.com

Sensei Biotherapeutics Inc trading halted, volatility trading pause

August 15 at 9:00 PM | msn.com

Q3 EPS Estimate for Sensei Biotherapeutics Lifted by Analyst

August 8, 2025 | americanbankingnews.com

Sensei (SNSE) Q2 Loss Narrows 31%

August 6, 2025 | fool.com

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 5, 2025 | globenewswire.com

These 3 health tech stocks spiked 37% in a day; Time to buy?

August 4, 2025 | finbold.comF

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

July 30, 2025 | globenewswire.com

Sensei Biotherapeutics to execute 1-for-20 reverse stock split

June 13, 2025 | kalkinemedia.comK

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

June 13, 2025 | globenewswire.com

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

May 6, 2025 | globenewswire.com

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

April 2, 2025 | globenewswire.com

Sensei Biotherapeutics announces initial results from solnerstotug trial portion

March 29, 2025 | markets.businessinsider.com

Sensei Rockets on FY ’24 Results

March 28, 2025 | baystreet.ca

Sensei Rockets on FY ’24 Results

March 28, 2025 | baystreet.ca

Sensei Biotherapeutics price target raised to $4 from $3.50 at Oppenheimer

March 28, 2025 | markets.businessinsider.com

Sensei Biotherapeutics price target raised to $4 from $3.50 at Oppenheimer

March 28, 2025 | markets.businessinsider.com

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

March 28, 2025 | globenewswire.com

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

March 27, 2025 | globenewswire.com

What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock

February 6, 2025 | zacks.com

Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

February 4, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SNSE, CALC, PLUR, and JSPR Company Descriptions

CalciMedica NASDAQ:CALC

$2.91 +0.30 (+11.49%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$2.88 -0.03 (-1.03%)

As of 08/15/2025 07:11 PM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Jasper Therapeutics NASDAQ:JSPR

$3.11 +0.08 (+2.64%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.06 -0.05 (-1.74%)

As of 08/15/2025 06:15 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Pluri NASDAQ:PLUR

$4.97 +0.13 (+2.69%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$4.42 -0.55 (-11.07%)

As of 08/15/2025 07:56 PM Eastern

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Sensei Biotherapeutics NASDAQ:SNSE

$8.68 +1.18 (+15.73%)

Closing price 08/15/2025 03:58 PM Eastern

Extended Trading

$8.03 -0.65 (-7.49%)

As of 08/15/2025 07:56 PM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time